Muscle-sparing obesity drug safe for Phase 3 trial, Veru says

Muscle-sparing obesity drug safe for Phase 3 trial, Veru says

The company is preparing a Phase 3 trial of enobosarm with a novel formulation that could extend its patent life.

Veru's Enobosarm Advances to Phase 3 Trials with Promising Safety Profile

Veru is advancing its muscle-preserving obesity drug, enobosarm, into Phase 3 trials following promising Phase 2 safety results. When combined with Novo Nordisk’s Wegovy, enobosarm showed fewer gastrointestinal side effects such as nausea and heartburn compared to Wegovy alone. Notably, the dose planned for Phase 3 testing demonstrated reduced occurrences of diarrhea and vomiting. However, some participants did experience elevated liver enzymes,…

Veru’s obesity drug roughly as safe as Wegovy; Keros’ board fight

Plus, news about Advanz, Alvotech and GeNeuro: Veru’s obesity drug generally safe when added to Wegovy: In the Phase 2b QUALITY trial, patients who were given enobosarm, an oral androgen receptor modulator ...